What ResMed Does

ResMed is a global leader in digital health, focusing primarily on cloud-connected medical devices for diagnosing, treating, and managing sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its core products include CPAP (continuous positive airway pressure) machines, masks, and ventilators. Crucially, ResMed has built a significant software-as-a-service (SaaS) business around its AirView platform, which remotely monitors patient device usage and therapy data, enabling healthcare providers to manage chronic conditions outside traditional clinical settings. Founded in 1989 and headquartered in San Diego with 5,001–10,000 employees, ResMed operates at the intersection of medical device manufacturing, digital health, and data analytics.

Why AI Matters at This Scale

For a company of ResMed's size and sector, AI is not a speculative trend but a strategic imperative to defend and extend its market leadership. The scale of its operations—millions of connected devices generating nightly patient data—creates a vast, underutilized asset. In a healthcare landscape shifting towards value-based care, payers reward outcomes and cost savings, not just device sales. AI provides the tools to translate raw data into predictive insights that improve patient adherence, enable early intervention, and reduce expensive hospitalizations. At its employee scale, ResMed can support dedicated data science and AI engineering teams, moving beyond pilot projects to enterprise-wide deployment, integrating AI into R&D, manufacturing, supply chain, and customer engagement.

Concrete AI Opportunities with ROI Framing

1. Predictive Patient Adherence & Care Management: By applying machine learning to usage patterns, mask leak data, and patient-reported outcomes, ResMed can identify individuals at high risk of abandoning therapy. Automated, personalized nudges (via app notifications or clinician alerts) can improve adherence. The ROI is direct: better adherence improves health outcomes, strengthens provider loyalty, and reduces costly patient churn and returns.

2. Enhanced Diagnostic Algorithms: AI can analyze signals from home sleep tests and therapy devices to more accurately detect complex sleep-disordered breathing events. This improves diagnostic precision, potentially expanding the treatable patient population and creating upsell opportunities for more advanced devices. The ROI includes increased market share in diagnostics and stronger clinical validation for its products.

3. AI-Optimized Global Supply Chain: With complex global manufacturing and distribution, AI demand forecasting can optimize inventory levels for masks and consumables, reducing carrying costs and stockouts. Predictive maintenance models for production equipment can minimize downtime. The ROI is measured in millions saved through operational efficiency and improved service levels.

Deployment Risks Specific to This Size Band

For a large, established firm like ResMed, key AI risks include integration complexity—embedding AI into legacy device firmware and enterprise systems (e.g., SAP, Salesforce) is slow and costly. Regulatory latency is paramount; any AI affecting patient care requires rigorous FDA clearance, creating a long development and approval cycle that can stall momentum. Data silos between departments (R&D, clinical, commercial) can hinder the creation of unified datasets needed for robust models. There's also cultural risk; shifting from a hardware-centric to an AI-driven software culture requires significant change management across thousands of employees. Finally, scaling pilots is challenging; proving an AI use case in one region or product line does not guarantee seamless global rollout due to varying data regulations and clinical practices.